

해외 바이오의약품 임상 현황 ('23년 12월 3주)

한국바이오의약품협회, 2023.12.26.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov

- 모니터링 기간: 2023.12.18.~2023.12.24.

- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06099782	A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)	Biological: Pembrolizumab co-formulated with hyaluronidase Biological: Pembrolizumab	Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT06099782&rank=1
NCT05840770	Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer	Procedure: Biospecimen Collection Biological: Cemiplimab Procedure: Computed Tomography Procedure: Magnetic Resonance Elastography Procedure: Positron Emission Tomography	City of Hope Medical Center National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT05840770&rank=1
NCT04466475	Radioimmunotherapy (211At-OKT10-B10) and Chemotherapy (Melphalan) Before Stem Cell Transplantation for the Treatment of Multiple Myeloma	Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Melphalan Procedure: Peripheral Blood Stem Cell Transplantation	Fred Hutchinson Cancer Center National Cancer Institute (NCI) National Institutes of Health (NIH)	Phase 1	https://clinicaltrials.gov/ct2/show/study?term=NCT04466475&rank=1
NCT06149286	A Trial to Learn if Odronektamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma	Drug: Odronektamab Drug: Lenalidomide Drug: Rituximab	Regeneron Pharmaceuticals	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT06149286&rank=1
NCT06178991	A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.	Biological: Influenza and COVID-19 Combination A Biological: Licensed influenza vaccine Biological: COVID-19 Vaccine Biological: Influenza and COVID-19 Combination B Biological: Placebo	BioNTech SE Pfizer	Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT06178991&rank=1

○ 영국 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06016920	Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma	Biological: VB10.16 Drug: Pembrolizumab	Nykode Therapeutics ASA Merck Sharp & Dohme LLC	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT06016920&rank=1

○ 중국 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05924776	Plasmodium Immunotherapy for Advanced Ovarian Cancer	Biological: Plasmodium immunotherapy	CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd. The Third Affiliated Hospital of Southern Medical University CAS Lamvac Biotech Co., Ltd.	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study?term=NCT05924776&rank=1
NCT06176885	Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer	Drug: Camrelizumab	yue junhan Jinhua Central Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study?term=NCT06176885&rank=1

해외 바이오의약품 임상 현황 ('23년 12월 3주)

한국바이오의약품협회, 2023.12.26.

○ 중국 6건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06170489	A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)	Biological: JS004 in combination with Toripalimab Drug: Bendamustine or gemcitabine	Shanghai Junshi Bioscience Co., Ltd.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT06170489
NCT06153368	Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC	Drug: Cadonilimab+mFOLFIRINOX	The First Affiliated Hospital with Nanjing Medical University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06153368
NCT06109402	Perioperative Immunotherapy Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer	Drug: TQB2450 Drug: Carboplatin Drug: Pemetrexed Drug: Nab-paclitaxel Procedure: Surgery	Shanghai Pulmonary Hospital, Shanghai, China	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06109402
NCT06105008	Study of Disitamab Vedotin With Toripalimab Versus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer	Drug: Disitamab Vedotin Drug: Toripalimab	RemeGen Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT06105008

○ 일본 1건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT06046742	A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors	Biological: M1-c6v1	Guangzhou Virotech Pharmaceutical Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT06046742